NTRR Continues Growth Strategy With New Joint Venture
News Jul 11, 2013
With this partnership, NTRR, a rapidly growing provider of all-natural wellness solutions, is taking the next step in capturing a share of the booming $1.7 billion medical marijuana (MMJ) market forecast to reach $6 billion over the next five years.
“Vertigo Technologies’ company focus is on the entire production cycle,” NTRR CEO Sydney Jim said. “Our goal is to bring advanced technology to this burgeoning industry and achieve efficiency and quality for the products and services we deliver.”
Through its subsidiary, Cannabis Technologies, NTRR is working to help introduce the next wave of healthier, more efficient delivery systems to the ever-growing MMJ market. By providing innovative nutraceutical products and services such as new MMJ breakthroughs, Neutra Corp. plans to follow in the footsteps of other successful public companies including Cannabis Science, Inc., Medical Marijuana Inc. and Terra Tech Corp., delivering technological advancements in the cultivation and processing of cannabis in approved markets.
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE